We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
No-reflow phenomenon during PCI in acute myocardial infarction.
- Authors
Ho Yan Angie Lam
- Abstract
No-reflow phenomenon complicates percutaneous coronary intervention in acute myocardial infarction. It significantly affects cardiac prognosis and clinical outcome. The underlying causes of no-reflow are ischaemia/reperfusion-related injury, coronary microcirculation injury and distal embolisation. Thrombolysis in myocardial infarction, myocardial blush grade and myocardial contrast echocardiography are commonly used to diagnose no-reflow phenomenon. Several pharmacological agents and mechanical devices effectively prevent and treat no-reflow. This article presents a patient with acute myocardial infarction who experienced no-reflow phenomenon during percutaneous coronary intervention. He is successfully treated with intracoronary nitroprusside, nitroglycerin (TNG), intra-arterial verapamil and intravenous abciximab.
- Subjects
MYOCARDIAL infarction complications; MYOCARDIAL infarction diagnosis; CORONARY heart disease prevention; MYOCARDIAL infarction; MYOCARDIAL infarction treatment; BIOMARKERS; ECHOCARDIOGRAPHY; HEMODYNAMICS; MYOCARDIAL reperfusion; MYOCARDIAL revascularization; NITROGLYCERIN; SODIUM nitroferricyanide; THROMBOLYTIC therapy; TRANSLUMINAL angioplasty; VERAPAMIL; TREATMENT effectiveness; ABCIXIMAB (Drug)
- Publication
British Journal of Cardiac Nursing, 2015, Vol 10, Issue 5, p223
- ISSN
1749-6403
- Publication type
Article
- DOI
10.12968/bjca.2015.10.5.223